تقرير
أعرض في EDS

Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph-negative acute lymphoblastic leukemia relapsed post CD19 CART therapy.

التفاصيل البيبلوغرافية
العنوان: Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph-negative acute lymphoblastic leukemia relapsed post CD19 CART therapy.
المؤلفون: Huang SM; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology Soochow University Suzhou China.; Collaborative Innovation Center of Hematology Soochow University Suzhou China., Wan CL; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology Soochow University Suzhou China.; Collaborative Innovation Center of Hematology Soochow University Suzhou China., Cao HY; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology Soochow University Suzhou China.; Collaborative Innovation Center of Hematology Soochow University Suzhou China., Li YY; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology Soochow University Suzhou China.; Collaborative Innovation Center of Hematology Soochow University Suzhou China., Qian CS; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology Soochow University Suzhou China.; Collaborative Innovation Center of Hematology Soochow University Suzhou China., Zhou HX; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology Soochow University Suzhou China.; Collaborative Innovation Center of Hematology Soochow University Suzhou China., Xu MZ; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology Soochow University Suzhou China.; Collaborative Innovation Center of Hematology Soochow University Suzhou China., Hu XH; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology Soochow University Suzhou China.; Collaborative Innovation Center of Hematology Soochow University Suzhou China., Dai L; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology Soochow University Suzhou China.; Collaborative Innovation Center of Hematology Soochow University Suzhou China., Dai HP; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology Soochow University Suzhou China.; Collaborative Innovation Center of Hematology Soochow University Suzhou China., Xue SL; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology Soochow University Suzhou China.; Collaborative Innovation Center of Hematology Soochow University Suzhou China.
المصدر: Clinical case reports [Clin Case Rep] 2023 Dec 09; Vol. 11 (12), pp. e8289. Date of Electronic Publication: 2023 Dec 09 (Print Publication: 2023).
نوع المنشور: Case Reports
اللغة: English
بيانات الدورية: Publisher: John Wiley & Sons Country of Publication: England NLM ID: 101620385 Publication Model: eCollection Cited Medium: Print ISSN: 2050-0904 (Print) Linking ISSN: 20500904 NLM ISO Abbreviation: Clin Case Rep Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Chichester, UK : John Wiley & Sons
مستخلص: There are no reports of application of inotuzumab ozogamicin (InO) for the treatment of MRD in r/r B-ALL. We firstly report the efficacy of InO for a patient experienced morphological relapse after HSCT and molecular relapse after CART therapy.
Competing Interests: The authors declare no competing interests.
(© 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.)
References: N Engl J Med. 2018 Feb 1;378(5):439-448. (PMID: 29385370)
Adv Ther. 2019 Apr;36(4):870-879. (PMID: 30847777)
Leuk Res. 2020 Jan;88:106283. (PMID: 31790983)
J Clin Oncol. 2014 Dec 20;32(36):4134-40. (PMID: 25385737)
Cancers (Basel). 2020 Jan 28;12(2):. (PMID: 32012891)
Cancer. 2019 Jul 15;125(14):2474-2487. (PMID: 30920645)
Hematology. 2019 Dec;24(1):337-348. (PMID: 30757960)
Pediatr Blood Cancer. 2023 Jan;70(1):e29852. (PMID: 35727716)
Blood. 2021 Jan 21;137(3):323-335. (PMID: 32967009)
Expert Opin Investig Drugs. 2012 Jun;21(6):871-8. (PMID: 22500551)
Bone Marrow Transplant. 2008 Mar;41(5):483-93. (PMID: 18026156)
N Engl J Med. 2016 Aug 25;375(8):740-53. (PMID: 27292104)
Ann Hematol. 2019 May;98(5):1259-1266. (PMID: 30635767)
Hematol Oncol. 2021 Oct;39(4):580-583. (PMID: 33963566)
Cancer. 2004 Dec 15;101(12):2788-801. (PMID: 15481055)
فهرسة مساهمة: Keywords: B‐ALL; CD22; MRD positive; inotuzumab ozogamicin; relapsed and refractory
تواريخ الأحداث: Date Created: 20231212 Latest Revision: 20231212
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10710375
DOI: 10.1002/ccr3.8289
PMID: 38084356
قاعدة البيانات: MEDLINE
الوصف
تدمد:2050-0904
DOI:10.1002/ccr3.8289